358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer.

Authors :: Bardia, A.
Spring, L.M.
Juric, D.
Partridge, A.
Ligibel, J.
Kuter, I.
Peppercorn, J.
Parsons, H.
Ryan, P.
Chawla, D.
Attaya, V.
Fitzgerald, D.M.
Viscosi, E.
Lormill, B.
Shellock, M.
Moy, B.
Tolaney, S.M.
Ellisen, L.W.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS394-S394. 1p.
Publication Year :: 2020

Subjects :: *TRIPLE-negative breast cancer
*METASTATIC breast cancer
*ANTIBODY-drug conjugates
*POLY(ADP-ribose) polymerase
*ERIBULIN

Full Text Access

Tools